Olvey, E., Clauschee, S., & Malone, D. (2010). Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. 87(1). https://doi.org/10.1038/clpt.2009.198

Yalkowsky, S., & Wu, C. (2010). Estimation of the ideal solubility (crystal-liquid fugacity ratio) of organic compounds. 99(3). https://doi.org/10.1002/jps.21897

Phan, H., Leder, M., Fishley, M., Moeller, M., & Nahata, M. (2010). Off-label and unlicensed medication use and associated adverse drug events in a pediatric emergency department. 26(6). https://doi.org/10.1097/PEC.0b013e3181e057e1

Conroy, J., Fang, D., Gu, J., Zeitlin, S., Yang, S., Yang, S., VanAlstine, M., Nalwalk, J., Albrecht, P., Mazurkiewicz, J., Snyder-Keller, A., Shan, Z., Zhang, D., Wentland, M., Behr, M., Knapp, S., Bidlack, J., Zuiderveld, O., Leurs, R., … Hough, L. (2010). Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. 13(3). https://doi.org/10.1038/nn.2497

Hall-Lipsy, E., & Chisholm-Burns, M. (2010). Pharmacotherapeutic disparities: racial, ethnic, and sex variations in medication treatment. 67(6). https://doi.org/10.2146/ajhp090161

Jain, P., & Yalkowsky, S. (2010). Prediction of aqueous solubility from SCRATCH. 385(1-2). https://doi.org/10.1016/j.ijpharm.2009.10.003

Thorne, C., Hanson, J., Schneider, L., Tahinci, E., Orton, D., Cselenyi, C., Jernigan, K., Meyers, K., Hang, B., Waterson, A., Kim, M., Melancon, B., Ghidu, V., Sulikowski, G., LaFleur, B., Salic, A., Lee, J., Miller, A., & Lee, J. (2010). Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. 6(11). https://doi.org/10.1038/nchembio.453

Lipsy, R. (2010). Will the newer oral MS agents be welcomed by managed care organizations?. 16(8 Suppl).

Warholak, T., McCulloch, M., Baumgart, A., Smith, T., Fink, W., & Fritz, K. (2009). An exploratory comparison of medication lists at hospital admission with administrative database records. 15(9). https://doi.org/10.18553/jmcp.2009.15.9.751

Lipsy, R., Schapiro, R., & Prostko, C. (2009). Current and future directions in MS management: key considerations for managed care pharmacists. 15(9 Suppl A).

Erstad, B., Puntillo, K., Gilbert, H., Grap, M., Li, X., Medina, J., Mularski, R., Pasero, C., Varkey, B., & Sessler, C. (2009). Pain management principles in the critically ill. 135(4). https://doi.org/10.1378/chest.08-2264

Erstad, B. (2008). A primer on critical care pharmacy services. 42(12). https://doi.org/10.1345/aph.1L375

Handley, L., Jackson, J., & Jackson, J. (2008). An evaluation of the validity of inferences made from 3 diabetes assessment instruments: a Rasch analysis. 4(1). https://doi.org/10.1016/j.sapharm.2007.04.002

Lipsy, R. (2008). Assessing the short-term and long-term burden of illness in cervical cancer. 14(6 Suppl 1).

Rupp, M., & Warholak, T. (2008). Evaluation of e-prescribing in chain community pharmacy: best-practice recommendations. 48(3). https://doi.org/10.1331/JAPhA.2008.07031

Weng, Y., Fang, D., Turesky, R., Behr, M., Kaminsky, L., & Ding, X. (2007). Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice. 67(16). https://doi.org/10.1158/0008-5472.CAN-07-1006

Buckley, M., Erstad, B., Kopp, B., Theodorou, A., & Priestley, G. (2007). Direct observation approach for detecting medication errors and adverse drug events in a pediatric intensive care unit. 8(2). https://doi.org/10.1097/01.PCC.0000257038.39434.04

Malone, D., Abarca, J., Skrepnek, G., Murphy, J., Armstrong, E., Grizzle, A., Rehfeld, R., & Woosley, R. (2007). Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions. 45(5). https://doi.org/10.1097/01.mlr.0000257839.83765.07

Lee, J., Grace, K., & Taylor, A. (2006). Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. 296(21). https://doi.org/10.1001/jama.296.21.joc60162

Kopp, B., Erstad, B., Allen, S., Theodorou, A., & Priestley, G. (2006). Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection. 34(2).

Dhanasekaran, M., Palian, M., Alves, I., Yeomans, L., Keyari, C., Davis, L., Bilsky, E., Egleton, R., Yamamura, H., Jacobsen, N., Tollin, G., Hruby, V., Porreca, F., & Polt, R. (2005). Glycopeptides related to beta-endorphin adopt helical amphipathic conformations in the presence of lipid bilayers. 127(15). https://doi.org/10.1021/ja0432158

Lipsy, R., Fuller, M., Roski, J., & Mansukani, S. (2004). Anticipating the future: how the emergence of innovative biologic agents impacts benefit design, utilization, and provider relations. 10(3 Suppl). https://doi.org/10.18553/jmcp.2004.10.S3-a.S4

Lipsy, R. (2004). Injectable biologic case studies. 10(3 Suppl).

Gu, J., Weng, Y., Zhang, D., Cui, Y., Behr, M., Wu, C., Yang, S., Zhang, D., & Ding, X. (2003). Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. 278(28). https://doi.org/10.1074/jbc.M303125200

Siddiqui-Jain, A., Grand, C., Bearss, D., & Hurley, L. (2002). Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. 99(18). https://doi.org/10.1073/pnas.182256799

Hurley, L. (2002). DNA and its associated processes as targets for cancer therapy. 2(3). https://doi.org/10.1038/nrc749

Kim, M., Vankayalapati, H., Shin-Ya, K., Wierzba, K., & Hurley, L. (2002). Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. 124(10). https://doi.org/10.1021/ja017308q

Macdonald, K., Brown, M., LaFleur, B., Peterson, K., Lawlor, C., Chen, Q., Packer, R., Cogen, P., & Stephan, D. (2001). Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. 29(2). https://doi.org/10.1038/ng731

Warholak-Juarez, T., Rupp, M., Salazar, F., & Foster, C. (2000). Effect of patient information on the quality of pharmacists’ drug use review decisions. 40(4).

Su, J., Bao, X., Zhang, D., Smith, T., Hong, J., & Ding, X. (2000). Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. 60(18).